BELPHARMA
ActiveSummary
BELPHARMA has been active since 1992 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €425,779 and a net result of €62,368. Equity is growing by about 9.9% per year across the filed financial years. Its solvency ranks better than 84% of 4,942 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
26-05
NBB filing
Annual accounts filed
financial year 2025 · full format
2025
26-05
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
03-06
NBB filing
Annual accounts filed
financial year 2023 · full format
2023
31-12
Financial
Highest result from 2018 to 2025net €66,700 ▲8.7%
Net result €66,700, the highest in the series.
01-06
NBB filing
Annual accounts filed
financial year 2022 · full format
2022
20-07
NBB filing
Annual accounts filed
financial year 2021 · full format
2021
17-06
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
29-05
NBB filing
Annual accounts filed
financial year 2019 · micro format
2019
27-05
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
28-05
NBB filing
Annual accounts filed
financial year 2017 · full format
2017
06-06
NBB filing
Annual accounts filed
financial year 2016 · full format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 34 annual accounts filed, the latest 10 are here; all 34 are under Financials.
0 of 5 deeds read
About the unread acts
We know of 5 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.